AMH and polycystic ovary syndrome: Seok et al.(37) studied the predictive role of anti-mullerian hormone (AMH) on the selection of IVM in patients with PCOS and concluded that AMH was a valuable factor in predicting clinical outcomes in such patients who preferred IVM as the treatment of choice.